These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1056 related articles for article (PubMed ID: 26861251)

  • 1. Efficacy of Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers in Coronary Artery Disease without Heart Failure in the Modern Statin Era: a Meta-Analysis of Randomized-Controlled Trials.
    Hoang V; Alam M; Addison D; Macedo F; Virani S; Birnbaum Y
    Cardiovasc Drugs Ther; 2016 Apr; 30(2):189-98. PubMed ID: 26861251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Effectiveness of Combination Therapy with Statins and Angiotensin-Converting Enzyme Inhibitors versus Angiotensin II Receptor Blockers in Patients with Coronary Heart Disease: A Nationwide Population-Based Cohort Study in Korea.
    Lee J; Lee S
    Pharmacotherapy; 2018 Nov; 38(11):1095-1105. PubMed ID: 30225928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis.
    Cheng J; Zhang W; Zhang X; Han F; Li X; He X; Li Q; Chen J
    JAMA Intern Med; 2014 May; 174(5):773-85. PubMed ID: 24687000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ACE-inhibitors versus angiotensin receptor blockers for prevention of events in cardiovascular patients without heart failure - A network meta-analysis.
    Ricci F; Di Castelnuovo A; Savarese G; Perrone Filardi P; De Caterina R
    Int J Cardiol; 2016 Aug; 217():128-34. PubMed ID: 27179902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular events in patients with heart failure: a meta-analysis of randomized controlled trials.
    Tai C; Gan T; Zou L; Sun Y; Zhang Y; Chen W; Li J; Zhang J; Xu Y; Lu H; Xu D
    BMC Cardiovasc Disord; 2017 Oct; 17(1):257. PubMed ID: 28982370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renin-angiotensin system antagonists and clinical outcomes in stable coronary artery disease without heart failure.
    Sorbets E; Labreuche J; Simon T; Delorme L; Danchin N; Amarenco P; Goto S; Meune C; Eagle KA; Bhatt DL; Steg PG
    Eur Heart J; 2014 Jul; 35(26):1760-8. PubMed ID: 24616336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular events and residual renal function in dialysis patients: a meta-analysis of randomised controlled trials.
    Liu Y; Ma X; Zheng J; Jia J; Yan T
    BMC Nephrol; 2017 Jun; 18(1):206. PubMed ID: 28666408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure.
    Savarese G; Costanzo P; Cleland JG; Vassallo E; Ruggiero D; Rosano G; Perrone-Filardi P
    J Am Coll Cardiol; 2013 Jan; 61(2):131-42. PubMed ID: 23219304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin receptor blockers for heart failure.
    Heran BS; Musini VM; Bassett K; Taylor RS; Wright JM
    Cochrane Database Syst Rev; 2012 Apr; 2012(4):CD003040. PubMed ID: 22513909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Outcomes in Heart Failure: A Meta-Analysis.
    Khan MS; Fonarow GC; Ahmed A; Greene SJ; Vaduganathan M; Khan H; Marti C; Gheorghiade M; Butler J
    Circ Heart Fail; 2017 Aug; 10(8):. PubMed ID: 28790052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Patients Without Heart Failure? Insights From 254,301 Patients From Randomized Trials.
    Bangalore S; Fakheri R; Toklu B; Ogedegbe G; Weintraub H; Messerli FH
    Mayo Clin Proc; 2016 Jan; 91(1):51-60. PubMed ID: 26763511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short- and long-term outcomes with renin-angiotensin-aldosterone inhibitors in renal transplant recipients: A meta-analysis of randomized controlled trials.
    Liao RX; Lyu XF; Tang WJ; Gao K
    Clin Transplant; 2017 Apr; 31(4):. PubMed ID: 28186357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Higher versus lower doses of ACE inhibitors, angiotensin-2 receptor blockers and beta-blockers in heart failure with reduced ejection fraction: Systematic review and meta-analysis.
    Turgeon RD; Kolber MR; Loewen P; Ellis U; McCormack JP
    PLoS One; 2019; 14(2):e0212907. PubMed ID: 30817783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blood pressure reduction and clinical outcomes with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: protocol for a systematic review and meta-regression analysis.
    Batty JA; Tang M; Hall M; Ferrari R; Strauss MH; Hall AS
    Syst Rev; 2018 Aug; 7(1):131. PubMed ID: 30144828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers After Coronary Artery Bypass Graft Surgery: A Population-Based Cohort Study.
    Barry AR; Helisaz H; Safari A; Loewen P
    J Am Heart Assoc; 2024 Jun; 13(12):e035215. PubMed ID: 38842283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct survival benefits of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers in revascularized coronary artery disease patients according to history of myocardial infarction.
    Nishino T; Furukawa Y; Kaji S; Ehara N; Shiomi H; Kim K; Kitai T; Kinoshita M; Morimoto T; Sakata R; Kimura T;
    Circ J; 2013; 77(5):1242-52. PubMed ID: 23291989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular outcomes in hypertensive patients with type 2 diabetes mellitus: A PRISMA-compliant systematic review and meta-analysis.
    Lv X; Zhang Y; Niu Y; Song Q; Zhao Q
    Medicine (Baltimore); 2018 Apr; 97(15):e0256. PubMed ID: 29642146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin Receptor-Neprilysin Inhibitor Effects on Atherosclerotic Cardiovascular Disease Events: A Meta-Analysis of Randomized Controlled Trials.
    Ravani LV; Gewehr DM; Calomeni P; Gauza MM; Pereira J; Cardoso R; Ribeiro HB; Bocchi E
    Am J Cardiol; 2023 Oct; 205():259-268. PubMed ID: 37619492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysis of randomized controlled trials.
    Lakhdar R; Al-Mallah MH; Lanfear DE
    J Card Fail; 2008 Apr; 14(3):181-8. PubMed ID: 18381180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
    Vijan SG
    J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.